-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Individual Investors Among Shanghai Bio-heart Biological Technology Co., Ltd.'s (HKG:2185) Largest Stockholders and Were Hit After Last Week's 6.9% Price Drop
Individual Investors Among Shanghai Bio-heart Biological Technology Co., Ltd.'s (HKG:2185) Largest Stockholders and Were Hit After Last Week's 6.9% Price Drop
A look at the shareholders of Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
And following last week's 6.9% decline in share price, individual investors suffered the most losses.
Let's delve deeper into each type of owner of Shanghai Bio-heart Biological Technology, beginning with the chart below.
See our latest analysis for Shanghai Bio-heart Biological Technology
SEHK:2185 Ownership Breakdown October 25th 2022What Does The Institutional Ownership Tell Us About Shanghai Bio-heart Biological Technology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Shanghai Bio-heart Biological Technology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shanghai Bio-heart Biological Technology's earnings history below. Of course, the future is what really matters.
SEHK:2185 Earnings and Revenue Growth October 25th 2022We note that hedge funds don't have a meaningful investment in Shanghai Bio-heart Biological Technology. Shanghai Baixinantong Enterprise Management Consulting L.P is currently the company's largest shareholder with 11% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 10% and 8.5%, of the shares outstanding, respectively.
On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
Insider Ownership Of Shanghai Bio-heart Biological Technology
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our data cannot confirm that board members are holding shares personally. It is rare to see such a low level of personal ownership, amongst the board (and it is possible that our data might be incomplete). Concerned investors should check here to see if insiders have been selling or buying.
General Public Ownership
With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shanghai Bio-heart Biological Technology. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Equity Ownership
With an ownership of 8.5%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Private Company Ownership
Our data indicates that Private Companies hold 20%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Shanghai Bio-heart Biological Technology that you should be aware of.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看上海生物心脏生物技术有限公司(HKG: 2185)的股东可以告诉我们哪个集团最强大。我们可以看到,个人投资者拥有公司的大部分股份,所有权为50%。也就是说,如果股票上涨,该集团将受益最大(如果股价下跌,则损失最大)。
继上周股价下跌6.9%之后,个人投资者遭受的损失最大。
让我们从下图开始,深入探讨上海生物心脏生物科技的每种类型的所有者。
查看我们对上海生物心脏生物技术的最新分析
SEHK: 2185 2022 年 10 月 25 日所有权明细关于上海生物心脏生物技术,机构所有权告诉我们什么?
机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。
上海百心生物科技股份有限公司已经在股份登记处设立了机构。事实上,他们在公司拥有可观的股份。这可以表明该公司在投资界具有一定程度的信誉。但是,最好谨慎行事,不要依赖机构投资者提供的假定验证。他们也是,有时候也会犯错。如果多个机构同时改变对一只股票的看法,你可能会看到股价迅速下跌。因此,下面值得一看上海生物心脏生物科技的盈利历史。当然,未来才是真正重要的。
SEHK: 2185 2022 年 10 月 25 日收益与收入增长我们注意到,对冲基金对上海生物心脏生物科技没有有意义的投资。上海百信通企业管理咨询有限责任公司目前是该公司的最大股东,拥有11%的已发行股份。同时,第二和第三大股东分别持有已发行股份的10%和8.5%。
经过进一步检查,我们发现公司一半以上的股份由前十名股东持有,这表明较大股东的利益在一定程度上被较小的股东所平衡。
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。我们目前没有收到分析师对该股的任何报道,因此该公司不太可能被广泛持有。
上海百心生物科技的内部所有权
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层经营业务,但首席执行官将对董事会负责,即使他或她是董事会成员。
大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。
我们的数据无法证实董事会成员亲自持有股份。在董事会中,很少见到如此低的个人所有权水平(而且我们的数据可能不完整)。有关投资者应在此处查看内部人士是否在卖出或买入。
一般公有制
拥有50%所有权的普通公众,主要由个人投资者组成,对上海生物心脏生物技术具有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
私募股权所有权
私募股权公司拥有8.5%的所有权,可以在制定以价值创造为重点的企业战略方面发挥作用。有时我们会看到私募股权长期存在,但总的来说,它们的投资期限较短,而且顾名思义,对上市公司的投资并不多。一段时间后,他们可能会考虑出售资本并将资本重新部署到其他地方。
私人公司所有权
我们的数据表明,私人公司持有公司20%的股份。私人公司可能是关联方。有时,内部人士通过持有私营公司的股权而对上市公司感兴趣,而不是以个人身份获得权益。虽然很难得出任何广泛的中风结论,但值得注意的是,这是一个有待进一步研究的领域。
后续步骤:
我觉得看看究竟是谁拥有一家公司非常有趣。但是,要真正获得见解,我们也需要考虑其他信息。例如,我们已经确定了 上海生物心脏生物技术有限公司有 1 个警告标志 你应该知道的。
当然 这可能不是最值得买的股票。因此,您不妨看看我们的 免费的 一系列具有良好财务状况的有趣潜在客户。
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧